Anuh Pharma Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: May 31, 2025, 8:15 pm

Market Cap	1,055 Cr.
Current Price	210
High / Low	250/148
Stock P/E	22.3
Book Value	65.1
Dividend Yield	1.19 %
ROCE	19.5 %
ROE	15.3 %
Face Value	5.00
PEG Ratio	1.85

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Anuh Pharma Ltd

Competitors of Anuh Pharma Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Lactose (India) Ltd	134 Cr.	95.0	247/84.3	26.0	41.7	0.00 %	12.9 %	9.75 %	10.0
MPS Pharmaa Ltd	5.27 Cr.	2.76	4.33/2.50		0.57	0.00 %	9.79 %	59.0 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	39.9 Cr.	53.8	94.9/44.5		8.73	0.00 %	41.5 %	14.4 %	10.0
Gujarat Inject (Kerala) Ltd	41.1 Cr.	28.0	29.1/13.1	40.3	6.83	0.00 %	13.5 %	11.0 %	10.0
Industry Average	18,354.98 Cr	1,129.60		88.53	194.54	0.32%	16.70%	15.22%	6.19

All Competitor Stocks of Anuh Pharma Ltd

Quarterly Result

Metric	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	129	116	115	139	157	161	150	172	164	138	166	160	198
Expenses	115	105	102	126	143	148	132	148	145	127	149	145	179
Operating Profit	14	11	13	12	14	14	18	24	19	11	17	15	19
OPM %	11%	10%	12%	9%	9%	9%	12%	14%	12%	8%	10%	9%	9%
Other Income	1	1	2	2	1	3	2	4	3	4	3	1	1
Interest	-0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	3	2	2	2	2	2	2	2	2	2	2	2	3
Profit before tax	12	10	13	12	13	15	18	25	20	12	18	13	17
Tax %	26%	24%	23%	23%	25%	24%	23%	24%	22%	22%	17%	22%	28%
Net Profit	9	7	10	9	10	12	14	19	15	10	15	10	12
EPS in Rs	1.78	1.46	1.98	1.86	1.92	2.34	2.76	3.81	3.07	1.90	3.00	2.06	2.49

Last Updated: May 31, 2025, 6:59 am

Below is a detailed analysis of the quarterly data for Anuh Pharma Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Sales, as of Mar 2025, the value is 198.00 Cr.. The value appears strong and on an upward trend. It has increased from 160.00 Cr. (Dec 2024) to 198.00 Cr., marking an increase of 38.00 Cr..
For Expenses, as of Mar 2025, the value is 179.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 145.00 Cr. (Dec 2024) to 179.00 Cr., marking an increase of 34.00 Cr..
For Operating Profit, as of Mar 2025, the value is 19.00 Cr.. The value appears strong and on an upward trend. It has increased from 15.00 Cr. (Dec 2024) to 19.00 Cr., marking an increase of 4.00 Cr..
For OPM %, as of Mar 2025, the value is 9.00%. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 9.00%.
For Other Income, as of Mar 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 1.00 Cr..
For Interest, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00 Cr..
For Depreciation, as of Mar 2025, the value is 3.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.00 Cr. (Dec 2024) to 3.00 Cr., marking an increase of 1.00 Cr..
For Profit before tax, as of Mar 2025, the value is 17.00 Cr.. The value appears strong and on an upward trend. It has increased from 13.00 Cr. (Dec 2024) to 17.00 Cr., marking an increase of 4.00 Cr..
For Tax %, as of Mar 2025, the value is 28.00%. The value appears to be increasing, which may not be favorable. It has increased from 22.00% (Dec 2024) to 28.00%, marking an increase of 6.00%.
For Net Profit, as of Mar 2025, the value is 12.00 Cr.. The value appears strong and on an upward trend. It has increased from 10.00 Cr. (Dec 2024) to 12.00 Cr., marking an increase of 2.00 Cr..
For EPS in Rs, as of Mar 2025, the value is 2.49. The value appears strong and on an upward trend. It has increased from 2.06 (Dec 2024) to 2.49, marking an increase of 0.43.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 2:04 pm

Metric	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	243	266	284	326	206	238	321	307	432	487	527	647	627
Expenses	225	242	253	289	183	220	291	284	387	439	476	571	566
Operating Profit	18	24	31	38	23	18	30	23	45	47	52	76	61
OPM %	7%	9%	11%	12%	11%	8%	9%	8%	10%	10%	10%	12%	10%
Other Income	2	4	5	4	8	7	5	4	11	5	6	12	11
Interest	1	1	1	1	1	0	1	1	2	2	1	1	1
Depreciation	2	2	3	2	2	2	2	7	15	12	10	9	8
Profit before tax	18	25	32	38	28	23	32	19	39	39	47	78	63
Tax %	29%	31%	31%	32%	27%	29%	28%	25%	26%	22%	24%	23%
Net Profit	13	18	22	26	20	17	23	14	28	31	36	60	50
EPS in Rs	2.50	3.51	4.39	5.15	4.00	3.30	4.66	2.86	5.68	6.10	7.22	11.99	10.03
Dividend Payout %	40%	37%	27%	24%	31%	42%	29%	48%	26%	29%	28%	21%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2013-2014	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	38.46%	22.22%	18.18%	-23.08%	-15.00%	35.29%	-39.13%	100.00%	10.71%	16.13%	66.67%
Change in YoY Net Profit Growth (%)	0.00%	-16.24%	-4.04%	-41.26%	8.08%	50.29%	-74.42%	139.13%	-89.29%	5.41%	50.54%

Anuh Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	9%
5 Years:	17%
3 Years:	11%
TTM:	2%

Compounded Profit Growth
10 Years:	9%
5 Years:	29%
3 Years:	18%
TTM:	-9%

Stock Price CAGR
10 Years:	7%
5 Years:	15%
3 Years:	31%
1 Year:	-8%

Return on Equity
10 Years:	15%
5 Years:	16%
3 Years:	16%
Last Year:	15%

Last Updated: Unknown

Balance Sheet

Last Updated: November 14, 2024, 5:52 pm

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	4	4	4	13	13	13	13	13	25	25	25	25	25
Reserves	71	82	97	107	128	137	152	150	166	189	216	266	278
Borrowings	1	0	0	2	0	2	4	45	14	4	1	3	14
Other Liabilities	60	77	67	71	48	57	71	119	128	129	163	152	117
Total Liabilities	136	163	168	193	189	209	240	326	333	347	405	446	434
Fixed Assets	10	12	9	18	17	17	21	84	71	61	53	49	46
CWIP	3	0	0	0	0	6	34	0	0	0	0	0	2
Investments	19	27	43	43	70	66	39	80	31	43	91	97	98
Other Assets	104	124	116	131	101	120	147	163	230	243	261	300	288
Total Assets	136	163	168	193	189	209	240	326	333	347	405	446	434

Below is a detailed analysis of the balance sheet data for Anuh Pharma Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Equity Capital, as of Sep 2024, the value is 25.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 25.00 Cr..
For Reserves, as of Sep 2024, the value is 278.00 Cr.. The value appears strong and on an upward trend. It has increased from 266.00 Cr. (Mar 2024) to 278.00 Cr., marking an increase of 12.00 Cr..
For Borrowings, as of Sep 2024, the value is 14.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 3.00 Cr. (Mar 2024) to 14.00 Cr., marking an increase of 11.00 Cr..
For Other Liabilities, as of Sep 2024, the value is 117.00 Cr.. The value appears to be improving (decreasing). It has decreased from 152.00 Cr. (Mar 2024) to 117.00 Cr., marking a decrease of 35.00 Cr..
For Total Liabilities, as of Sep 2024, the value is 434.00 Cr.. The value appears to be improving (decreasing). It has decreased from 446.00 Cr. (Mar 2024) to 434.00 Cr., marking a decrease of 12.00 Cr..
For Fixed Assets, as of Sep 2024, the value is 46.00 Cr.. The value appears to be declining and may need further review. It has decreased from 49.00 Cr. (Mar 2024) to 46.00 Cr., marking a decrease of 3.00 Cr..
For CWIP, as of Sep 2024, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2024) to 2.00 Cr., marking an increase of 2.00 Cr..
For Investments, as of Sep 2024, the value is 98.00 Cr.. The value appears strong and on an upward trend. It has increased from 97.00 Cr. (Mar 2024) to 98.00 Cr., marking an increase of 1.00 Cr..
For Other Assets, as of Sep 2024, the value is 288.00 Cr.. The value appears to be declining and may need further review. It has decreased from 300.00 Cr. (Mar 2024) to 288.00 Cr., marking a decrease of 12.00 Cr..
For Total Assets, as of Sep 2024, the value is 434.00 Cr.. The value appears to be declining and may need further review. It has decreased from 446.00 Cr. (Mar 2024) to 434.00 Cr., marking a decrease of 12.00 Cr..

Notably, the Reserves (278.00 Cr.) exceed the Borrowings (14.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity +	15	19	16	26	2	7	49	-19	29	54	13	37
Cash from Investing Activity +	-5	-12	-5	-20	2	3	-77	52	-8	-43	1	-20
Cash from Financing Activity +	-8	-8	-9	-4	-5	-7	22	-33	-19	-12	-9	-5
Net Cash Flow	2	-1	2	2	-1	3	-5	0	2	-2	5	12

Free Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	17.00	24.00	31.00	36.00	23.00	16.00	26.00	-22.00	31.00	43.00	51.00	73.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	82	102	88	84	100	109	85	96	90	102	118	107
Inventory Days	43	33	27	35	72	64	64	98	90	77	66	57
Days Payable	86	102	79	77	102	105	89	166	133	117	139	105
Cash Conversion Cycle	39	33	36	42	70	68	61	28	48	62	46	58
Working Capital Days	45	42	43	51	79	83	70	44	68	70	61	68
ROCE %	26%	31%	33%	35%	19%	14%	19%	10%	16%	18%	19%	26%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoters	70.43%	70.59%	70.59%	70.59%	70.59%	70.59%	70.59%	69.94%	69.91%	69.91%	69.91%	69.91%
FIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.03%	0.03%	0.02%	0.02%
DIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.10%	0.00%	0.00%	0.00%
Public	29.56%	29.42%	29.41%	29.40%	29.40%	29.39%	29.40%	30.05%	29.96%	30.05%	30.06%	30.06%
No. of Shareholders	21,123	20,740	20,452	20,470	19,969	19,423	19,066	20,519	22,237	23,494	23,910	24,048

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	5.00	5.00	5.00	5.00	5.00
Basic EPS (Rs.)	11.98	7.22	6.10	5.67	5.71
Diluted EPS (Rs.)	11.98	7.22	6.10	5.67	5.71
Cash EPS (Rs.)	13.70	9.15	8.48	8.68	8.52
Book Value[Excl.RevalReserv]/Share (Rs.)	58.11	48.14	42.66	38.04	64.74
Book Value[Incl.RevalReserv]/Share (Rs.)	58.11	48.14	42.66	38.04	64.74
Dividend / Share (Rs.)	2.50	2.00	1.75	1.50	2.75
Revenue From Operations / Share (Rs.)	129.11	105.26	97.11	86.20	122.51
PBDIT / Share (Rs.)	17.41	11.45	10.39	11.00	10.77
PBIT / Share (Rs.)	15.70	9.52	8.00	7.99	7.96
PBT / Share (Rs.)	15.63	9.47	7.81	7.69	7.64
Net Profit / Share (Rs.)	11.98	7.22	6.10	5.67	5.71
PBDIT Margin (%)	13.48	10.87	10.69	12.76	8.78
PBIT Margin (%)	12.15	9.04	8.23	9.27	6.49
PBT Margin (%)	12.10	8.99	8.03	8.92	6.24
Net Profit Margin (%)	9.28	6.85	6.27	6.58	4.66
Return on Networth / Equity (%)	20.62	14.99	14.29	14.91	8.81
Return on Capital Employeed (%)	26.84	19.57	18.53	20.73	12.18
Return On Assets (%)	13.47	8.93	8.80	8.54	4.38
Total Debt / Equity (X)	0.01	0.00	0.01	0.07	0.27
Asset Turnover Ratio (%)	1.52	1.40	1.43	1.31	1.08
Current Ratio (X)	2.20	1.91	1.98	1.70	1.37
Quick Ratio (X)	1.71	1.46	1.37	1.12	0.99
Inventory Turnover Ratio (X)	6.62	4.94	4.36	4.53	4.59
Dividend Payout Ratio (NP) (%)	16.68	24.23	24.59	0.00	96.33
Dividend Payout Ratio (CP) (%)	14.60	19.11	17.67	0.00	64.58
Earning Retention Ratio (%)	83.32	75.77	75.41	0.00	3.67
Cash Earning Retention Ratio (%)	85.40	80.89	82.33	0.00	35.42
Interest Coverage Ratio (X)	246.74	262.77	54.16	36.88	34.06
Interest Coverage Ratio (Post Tax) (X)	170.85	166.66	32.80	20.03	19.06
Enterprise Value (Cr.)	1223.09	392.34	417.88	446.02	334.07
EV / Net Operating Revenue (X)	1.89	0.74	0.85	1.03	1.09
EV / EBITDA (X)	14.02	6.84	8.03	8.09	12.38
MarketCap / Net Operating Revenue (X)	1.90	0.75	0.88	1.05	0.95
Retention Ratios (%)	83.31	75.76	75.40	0.00	3.66
Price / BV (X)	4.23	1.65	2.01	2.37	1.80
Price / Net Operating Revenue (X)	1.90	0.75	0.88	1.05	0.95
EarningsYield	0.04	0.09	0.07	0.06	0.04

After reviewing the key financial ratios for Anuh Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 5.00.
For Basic EPS (Rs.), as of Mar 24, the value is 11.98. This value is within the healthy range. It has increased from 7.22 (Mar 23) to 11.98, marking an increase of 4.76.
For Diluted EPS (Rs.), as of Mar 24, the value is 11.98. This value is within the healthy range. It has increased from 7.22 (Mar 23) to 11.98, marking an increase of 4.76.
For Cash EPS (Rs.), as of Mar 24, the value is 13.70. This value is within the healthy range. It has increased from 9.15 (Mar 23) to 13.70, marking an increase of 4.55.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 58.11. It has increased from 48.14 (Mar 23) to 58.11, marking an increase of 9.97.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 58.11. It has increased from 48.14 (Mar 23) to 58.11, marking an increase of 9.97.
For Dividend / Share (Rs.), as of Mar 24, the value is 2.50. This value is within the healthy range. It has increased from 2.00 (Mar 23) to 2.50, marking an increase of 0.50.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 129.11. It has increased from 105.26 (Mar 23) to 129.11, marking an increase of 23.85.
For PBDIT / Share (Rs.), as of Mar 24, the value is 17.41. This value is within the healthy range. It has increased from 11.45 (Mar 23) to 17.41, marking an increase of 5.96.
For PBIT / Share (Rs.), as of Mar 24, the value is 15.70. This value is within the healthy range. It has increased from 9.52 (Mar 23) to 15.70, marking an increase of 6.18.
For PBT / Share (Rs.), as of Mar 24, the value is 15.63. This value is within the healthy range. It has increased from 9.47 (Mar 23) to 15.63, marking an increase of 6.16.
For Net Profit / Share (Rs.), as of Mar 24, the value is 11.98. This value is within the healthy range. It has increased from 7.22 (Mar 23) to 11.98, marking an increase of 4.76.
For PBDIT Margin (%), as of Mar 24, the value is 13.48. This value is within the healthy range. It has increased from 10.87 (Mar 23) to 13.48, marking an increase of 2.61.
For PBIT Margin (%), as of Mar 24, the value is 12.15. This value is within the healthy range. It has increased from 9.04 (Mar 23) to 12.15, marking an increase of 3.11.
For PBT Margin (%), as of Mar 24, the value is 12.10. This value is within the healthy range. It has increased from 8.99 (Mar 23) to 12.10, marking an increase of 3.11.
For Net Profit Margin (%), as of Mar 24, the value is 9.28. This value is within the healthy range. It has increased from 6.85 (Mar 23) to 9.28, marking an increase of 2.43.
For Return on Networth / Equity (%), as of Mar 24, the value is 20.62. This value is within the healthy range. It has increased from 14.99 (Mar 23) to 20.62, marking an increase of 5.63.
For Return on Capital Employeed (%), as of Mar 24, the value is 26.84. This value is within the healthy range. It has increased from 19.57 (Mar 23) to 26.84, marking an increase of 7.27.
For Return On Assets (%), as of Mar 24, the value is 13.47. This value is within the healthy range. It has increased from 8.93 (Mar 23) to 13.47, marking an increase of 4.54.
For Total Debt / Equity (X), as of Mar 24, the value is 0.01. This value is within the healthy range. It has increased from 0.00 (Mar 23) to 0.01, marking an increase of 0.01.
For Asset Turnover Ratio (%), as of Mar 24, the value is 1.52. It has increased from 1.40 (Mar 23) to 1.52, marking an increase of 0.12.
For Current Ratio (X), as of Mar 24, the value is 2.20. This value is within the healthy range. It has increased from 1.91 (Mar 23) to 2.20, marking an increase of 0.29.
For Quick Ratio (X), as of Mar 24, the value is 1.71. This value is within the healthy range. It has increased from 1.46 (Mar 23) to 1.71, marking an increase of 0.25.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 6.62. This value is within the healthy range. It has increased from 4.94 (Mar 23) to 6.62, marking an increase of 1.68.
For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 16.68. This value is below the healthy minimum of 20. It has decreased from 24.23 (Mar 23) to 16.68, marking a decrease of 7.55.
For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 14.60. This value is below the healthy minimum of 20. It has decreased from 19.11 (Mar 23) to 14.60, marking a decrease of 4.51.
For Earning Retention Ratio (%), as of Mar 24, the value is 83.32. This value exceeds the healthy maximum of 70. It has increased from 75.77 (Mar 23) to 83.32, marking an increase of 7.55.
For Cash Earning Retention Ratio (%), as of Mar 24, the value is 85.40. This value exceeds the healthy maximum of 70. It has increased from 80.89 (Mar 23) to 85.40, marking an increase of 4.51.
For Interest Coverage Ratio (X), as of Mar 24, the value is 246.74. This value is within the healthy range. It has decreased from 262.77 (Mar 23) to 246.74, marking a decrease of 16.03.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 170.85. This value is within the healthy range. It has increased from 166.66 (Mar 23) to 170.85, marking an increase of 4.19.
For Enterprise Value (Cr.), as of Mar 24, the value is 1,223.09. It has increased from 392.34 (Mar 23) to 1,223.09, marking an increase of 830.75.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 1.89. This value is within the healthy range. It has increased from 0.74 (Mar 23) to 1.89, marking an increase of 1.15.
For EV / EBITDA (X), as of Mar 24, the value is 14.02. This value is within the healthy range. It has increased from 6.84 (Mar 23) to 14.02, marking an increase of 7.18.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 1.90. This value is within the healthy range. It has increased from 0.75 (Mar 23) to 1.90, marking an increase of 1.15.
For Retention Ratios (%), as of Mar 24, the value is 83.31. This value exceeds the healthy maximum of 70. It has increased from 75.76 (Mar 23) to 83.31, marking an increase of 7.55.
For Price / BV (X), as of Mar 24, the value is 4.23. This value exceeds the healthy maximum of 3. It has increased from 1.65 (Mar 23) to 4.23, marking an increase of 2.58.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 1.90. This value is within the healthy range. It has increased from 0.75 (Mar 23) to 1.90, marking an increase of 1.15.
For EarningsYield, as of Mar 24, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.09 (Mar 23) to 0.04, marking a decrease of 0.05.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Anuh Pharma Ltd as of June 1, 2025 is: 179.81

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of June 1, 2025, Anuh Pharma Ltd is Overvalued by 14.38% compared to the current share price 210.00

Intrinsic Value of Anuh Pharma Ltd as of June 1, 2025 is: 201.47

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of June 1, 2025, Anuh Pharma Ltd is Overvalued by 4.06% compared to the current share price 210.00

Last 5 Year EPS CAGR: 12.04%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 22.17%, which is a positive sign. The company has higher reserves (156.85 cr) compared to borrowings (6.92 cr), indicating strong financial stability. The company has shown consistent growth in sales (377.77 cr) and profit (37.00 cr) over the years.	The stock has a high average Working Capital Days of 60.33, which may not be favorable. The stock has a high average Cash Conversion Cycle of 49.25, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Anuh Pharma Ltd:
1. Net Profit Margin: 9.28%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 26.84% (Industry Average ROCE: 16.7%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 20.62% (Industry Average ROE: 15.22%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 170.85
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 1.71
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 22.3 (Industry average Stock P/E: 88.53)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.01
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Anuh Pharma Ltd. is a Public Limited Listed company incorporated on 19/02/1960 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24230MH1960PLC011586 and registration number is 011586. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 661.51 Cr. and Equity Capital is Rs. 25.06 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	3-A, Shivsagar Estate, Mumbai Maharashtra 400018	anuh@sk1932.com http://www.anuhpharma.com

Management
Name	Position Held
Mr. Arun Todarwal	Chairman & Non-Exe.Director
Mr. Bipin N Shah	Vice Chairman
Mr. Ritesh B Shah	Joint Managing Director
Mr. Vivek B Shah	Joint Managing Director
Mr. Sandeep Joshi	Independent Director
Mr. Harmanbhai Patel	Independent Director
Dr.(Ms.) Mita Dixit	Independent Director
Mr. Siddharth J Shah	Independent Director
Mr. Pradeep H Thakur	Independent Director
Mr. Ketan Shah	Non Executive Director
Mr. Bharat Shah	Non Executive Director
Mr. Samir Shah	Non Executive Director
Mr. Gaurav S Shah	Non Executive Director

FAQ

What is the intrinsic value of Anuh Pharma Ltd?

Anuh Pharma Ltd's intrinsic value (as of 31 May 2025) is ₹179.81 — 14.38% lower the current market price of 210.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 1,055 Cr. market cap, FY2025-2026 high/low of ₹250/148, reserves of 278 Cr, and liabilities of 434 Cr.

What is the Market Cap of Anuh Pharma Ltd?

The Market Cap of Anuh Pharma Ltd is 1,055 Cr..

What is the current Stock Price of Anuh Pharma Ltd as on 31 May 2025?

The current stock price of Anuh Pharma Ltd as on 31 May 2025 is 210.

What is the High / Low of Anuh Pharma Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Anuh Pharma Ltd stocks is ₹250/148.

What is the Stock P/E of Anuh Pharma Ltd?

The Stock P/E of Anuh Pharma Ltd is 22.3.

What is the Book Value of Anuh Pharma Ltd?

The Book Value of Anuh Pharma Ltd is 65.1.

What is the Dividend Yield of Anuh Pharma Ltd?

The Dividend Yield of Anuh Pharma Ltd is 1.19 %.

What is the ROCE of Anuh Pharma Ltd?

The ROCE of Anuh Pharma Ltd is 19.5 %.

What is the ROE of Anuh Pharma Ltd?

The ROE of Anuh Pharma Ltd is 15.3 %.

What is the Face Value of Anuh Pharma Ltd?

The Face Value of Anuh Pharma Ltd is 5.00.